Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China

PURPOSE: Anlotinib, a novel multi-target tyrosine kinase inhibitor, has shown encouraging antitumor effects in advanced hepatocellular carcinoma (HCC). This study evaluated the effectiveness and safety of anlotinib with or without programmed death-1 (PD-1) blockades for patients with advanced primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao-Qi, Zhao, Yun-Xia, Zhang, Chuan-Lei, Wang, Xin-Ting, Zhang, Xin, Chen, Xi, Yuan, Chang-Wei, Zhao, Qing, Chen, Xin-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123907/
https://www.ncbi.nlm.nih.gov/pubmed/35607597
http://dx.doi.org/10.2147/DDDT.S358092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123907/
https://www.ncbi.nlm.nih.gov/pubmed/35607597
http://dx.doi.org/10.2147/DDDT.S358092

Ejemplares similares